Skip to main content

Table 3 Distribution of participants by wave, age, and formulation

From: Development and content validation of the Pediatric Oral Medicines Acceptability Questionnaires (P-OMAQ): patient-reported and caregiver-reported outcome measures

Age Liquid, n Powders, n Pills or tablets, n Number of interviews, n
Wave 1
 6 months to 5 years a 1 1 0 2
 6–7 years b 1 2 0 3
 8–11 years b 2 0 3 5
 12–17 years c 1e 0 1 2
 Subtotal 5 3 4 12
Wave 2
 6 months to 5 years a 2 2d 2 6
 6–7 years b 0 0 0 0
 8–11 years b 1 1 1 3
 12–17 years c 2 1 1 4
 Subtotal 5 4 4 13
Wave 3
 6 months to 5 years a 1 2 2 5
 6–7 years b 0 1 0 1
 8–11 years b 0 1 0 1
 12–17 years c 1 1 2 4
 Subtotal 2 5 4 11
Wave 4 e
 8–11 years b 4 4 4 12
 Subtotal 4 4 4 12
Total 16 16 16 48
  1. Concept elicitation interviews were not carried out during Wave 4, and only patients aged 8–17 years and caregivers of all patients were included in the cognitive debriefing interviews
  2. aCaregiver only
  3. bPatient and caregiver
  4. cPatient (caregivers were invited to participate); separate consent was gathered from the patient and the caregiver
  5. dThe patient administered her/his medicine through a nebulizer
  6. eThe goal of the Wave 4 interviews was to cognitively debrief the questionnaire among the youngest age group that would be asked to complete the questionnaire; therefore, only participants aged 8–11 years were asked to participate in this wave of interviews